Literature DB >> 24307292

Inflammatory plasma markers and risk for venous thromboembolism.

Signy V Sveinsdottir1, Peter J Svensson, Gunnar Engström.   

Abstract

Venous thromboembolism (VTE) and arterial thrombosis have been thought to result from two different mechanisms. Recent data indicate that the two diseases may share some common risk factors, such as the activity of inflammation on haemostasis. In this population-based study we explored whether raised levels of inflammation-sensitive plasma markers (ISPs) increase the risk for venous thromboembolism. Measurements of five ISPs (fibrinogen, haptoglobin, ceruloplasmin, α1-antitrypsin and orosomucoid) were performed in 6,068 subjects from "the Malmö Preventive Study". These apparently healthy men from the city of Malmö in Sweden, were included in the study between 1974 and 1982 and followed up until 2008. We calculated the hazard ratio (HR) for VTE in relation to the number of raised ISPs as well as individual ISPs in the fourth quartile. Mean follow-up time was 26.2 years. Out of the cohort (n = 6,068), 398 (6.6%) had a venous thromboembolism during the follow-up. The number of raised ISPs was significantly associated with age, BMI and smoking. Age, BMI and diabetes mellitus type 2 were also significant risk factors for developing a VTE (HR = 1.05 with p < 0.01 and 95% CI 1.01-1.08, HR = 1.10 with p < 0.001 and 95% CI 1.06-1.14 and HR = 1.78 with p < 0.05 and 95% CI 1.13-2.81, respectively). Incidence of venous thromboembolism was not significantly related to number of raised inflammatory proteins (p for trend = 0.37) or any of the individual ISPs. Age and BMI is significantly associated with the risk for developing VTE. Incidence of VTE was not associated with any of the inflammatory proteins.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24307292     DOI: 10.1007/s11239-013-1033-6

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  33 in total

1.  C-reactive protein, idiopathic venous thromboembolism and hormone replacement therapy.

Authors:  G Lowe; A Rumley; M Woodward; M Vessey
Journal:  Thromb Haemost       Date:  2000-10       Impact factor: 5.249

2.  Long-term effects of inflammation-sensitive plasma proteins and systolic blood pressure on incidence of stroke.

Authors:  G Engström; P Lind; B Hedblad; L Stavenow; L Janzon; F Lindgärde
Journal:  Stroke       Date:  2002-12       Impact factor: 7.914

Review 3.  A systematic review of validated methods for identifying venous thromboembolism using administrative and claims data.

Authors:  Leonardo Tamariz; Thomas Harkins; Vinit Nair
Journal:  Pharmacoepidemiol Drug Saf       Date:  2012-01       Impact factor: 2.890

4.  An association between atherosclerosis and venous thrombosis.

Authors:  Paolo Prandoni; Franca Bilora; Antonio Marchiori; Enrico Bernardi; Francesco Petrobelli; Anthonie W A Lensing; Martin H Prins; Antonio Girolami
Journal:  N Engl J Med       Date:  2003-04-10       Impact factor: 91.245

5.  Statins reduce interleukin-6-induced C-reactive protein in human hepatocytes: new evidence for direct antiinflammatory effects of statins.

Authors:  Claire Arnaud; Fabienne Burger; Sabine Steffens; Niels R Veillard; Tuan Huy Nguyen; Didier Trono; François Mach
Journal:  Arterioscler Thromb Vasc Biol       Date:  2005-03-24       Impact factor: 8.311

6.  Deep venous thrombosis in peripheral vascular disease.

Authors:  G Libertiny; L Hands
Journal:  Br J Surg       Date:  1999-07       Impact factor: 6.939

7.  Effects of cholesterol and inflammation-sensitive plasma proteins on incidence of myocardial infarction and stroke in men.

Authors:  G Engström; P Lind; B Hedblad; L Stavenow; L Janzon; F Lindgärde
Journal:  Circulation       Date:  2002-06-04       Impact factor: 29.690

8.  Cardiovascular risk factors and venous thromboembolism incidence: the longitudinal investigation of thromboembolism etiology.

Authors:  Albert W Tsai; Mary Cushman; Wayne D Rosamond; Susan R Heckbert; Joseph F Polak; Aaron R Folsom
Journal:  Arch Intern Med       Date:  2002-05-27

9.  Cardiovascular risk factors and venous thromboembolism: a meta-analysis.

Authors:  Walter Ageno; Cecilia Becattini; Timothy Brighton; Rita Selby; Pieter W Kamphuisen
Journal:  Circulation       Date:  2007-12-17       Impact factor: 29.690

10.  External review and validation of the Swedish national inpatient register.

Authors:  Jonas F Ludvigsson; Eva Andersson; Anders Ekbom; Maria Feychting; Jeong-Lim Kim; Christina Reuterwall; Mona Heurgren; Petra Otterblad Olausson
Journal:  BMC Public Health       Date:  2011-06-09       Impact factor: 3.295

View more
  4 in total

1.  Circulating ceruloplasmin, ceruloplasmin-associated genes and the incidence of venous thromboembolism in the Atherosclerosis Risk in Communities study.

Authors:  Antonio P Arenas de Larriva; Alvaro Alonso; Faye L Norby; Nicholas S Roetker; Aaron R Folsom
Journal:  J Thromb Haemost       Date:  2019-03-18       Impact factor: 5.824

2.  Risk factors for venous thromboembolism in patients undergoing craniotomy for neoplastic disease.

Authors:  Kristopher T Kimmell; Kevin A Walter
Journal:  J Neurooncol       Date:  2014-08-23       Impact factor: 4.130

Review 3.  Diabetes mellitus and venous thromboembolism: A systematic review and meta-analysis.

Authors:  Elizabeth J Bell; Aaron R Folsom; Pamela L Lutsey; Elizabeth Selvin; Neil A Zakai; Mary Cushman; Alvaro Alonso
Journal:  Diabetes Res Clin Pract       Date:  2015-11-10       Impact factor: 5.602

4.  Haematological variables and risk of future venous thromboembolism in the British Regional Heart Study on men. Combined D-dimer and APTT as a predictive test for thromboembolism?

Authors:  S Goya Wannamethee; Olia Papacosta; Lucy Lennon; Peter H Whincup; Ann Rumley; Gordon D O Lowe
Journal:  Br J Haematol       Date:  2022-06-02       Impact factor: 8.615

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.